From: Risk factors for the recurrence of relapsing polychondritis
PM | PC | P value | |
---|---|---|---|
n=23 | n=11 | ||
Age at onset (years) | 52 (45–70) | 46 (30–58) | 0.1616 |
Female, n (%) | 13 (56.5) | 4 (36.4) | 0.4646 |
Disease duration (years) | 5.5 (2.9–6.8) | 4.5 (1.8–12.9) | 0.6720 |
Time until diagnosis (days) | 151 (78–270) | 105 (91–235) | 0.8684 |
Time until treatment (days) | 151 (78–270) | 156 (99–467) | 0.6586 |
Initial symptoms, n (%) | |||
Auricular | 18 (78.3) | 5 (45.5) | 0.1143 |
Tracheobronchial | 4 (17.4) | 7 (63.6) | 0.0160 |
RPDAI | 23 (15–41) | 33 (22–35) | 0.2851 |
WBC (/μl) | 7000 (5500–8200), n=15 | 7710 (6325–8375), n=9 | 0.5913 |
Monocyte (/μl) | 444 (308–596), n=15 | 430 (388–471), n=9 | 0.8815 |
Hb (g/dl) | 12.4 (10.8–13.9), n=15 | 11.8 (10.4–13.8), n=10 | 0.6570 |
Plt (×104/μl) | 30.1 (21.5–32.7), n=15 | 33.9 (26.6–49.4), n=10 | 0.0521 |
CRP (mg/dl) | 2.8 (0.5–4.7), n=16 | 4.5 (1.6–8.7), n=9 | 0.4270 |
ESR (mm/h) | 70 (43–104), n=12 | 55 (22–102), n=10 | 0.5977 |
IgG (mg/dl) | 1432 (1229–1709), n=12 | 1597 (984–2020), n=10 | 0.7416 |
Initial PSL doses (mg) | 28 (13.8–41.2), n=22 | 40 (15–70), n=11 | 0.2566 |
PSL doses at initial recurrence (mg) | 10 (5–14), n=16 | 10 (6.5–12), n=9 | 0.9319 |
PSL dose reduction until initial recurrence (mg/day) | 0.1 (0.03–0.4), n=15 | 0.03 (0.015–0.2), n=9 | 0.2691 |
Time until initial recurrence (days) | 70 (26–211) | 400 (294–1446) | 0.0015 |